Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Rs will be 15-1. $7.50 ought to be secure.
How many companies have compounds with inferior data yet have partnership deals ? (not necessarily in hiv space). Some of them are questionable, yet what seems like a home run to us is ignored. I am questioning adding to my position when more $$ becomes available. Or is BP like Hollywood in that they can be soooo wrong in such a big way. When they find something that makes money, they scour everything they can in that area. But they are loathe (?) to go into new areas and innovate. Just rambling.
Almost all of Wall St cannot invest in CYDY. The company is sorely undervalued. Uplisting will change valuations to some degree, especially when accompanied by trial results or other developments.
If things go well, $20 per share. $20 Bill is a stretch, IMO.
If there is going to be a buyout in a couple months, or even a couple quarters ... this does not seem likely to be able to add to any buyout price. But after a year or so, they might have done a few animal pre-clinicals. This should convey the broad uses for Pro140, and thus enter into the .... calculus (?) of a buyout price. I do not guess we are near the endgame.
More than half of the volume is short ? Wow
I’m waiting on red tape and account transfers to buy more. Not patiently, I might add
I hope so, terd. I will be buying more
I was hoping to be able to add to my position (especially at these prices) but it will likely be another month.
Or perhaps dosage was increased to hopefully beat all the existing therapies ? Is that over-exuberance ?
In the cd01 extension 2b study, 350mg gave 81.3% suppression over 40 weeks. That’s no guarantee, but that is quite reassuring for phase 3.
Yes thanks. The company has been saying 150 for a long time now, so more than 250. And is this new to anybody else ? From Croi last year, but some graphics I’ve never seen before. http://www.croiconference.org/sites/default/files/posters-2017/437_Dhody.pdf
If it’s anything like combo HIV trial, then it’s that the 10th patient is still waiting to be enrolled. But I don’t know.
“Maybe mono enrollment is complete now, “
I remember thinking that a couple of times for the combo trial. Mono is different but still, history is against you on assuming progress that hasn’t been announced.
Yet another reason for a fricking conference call; all IR can say is to repeat 6 month old PR’s. 3-4 weeks to go until we hear something
Thank you for clarifying. You remember those math problems with lots of numbers and only a few of them are relevant ? I think I was working with the wrong numbers.
That is market potential. Pro140 will only get a fraction of that $1.2 Bill or $3.8 Bill per year. That assumes 100% of Hart failures for combo and 17.5% of Hart patients for mono. Isn’t that too optimistic ? Still dividing by 2 means $2.5 Bill per year.
FDA approval might not get us above $2 while on OTC. It’s necessary. Bring it on. Or are you chicken ? : - )
At least 10, IMO.
I take the increasing false FUD as confirmation that wonderful things are ahead.
Last 8 days volume has been less than 100K except when the R/S was announced. I hope to have more cash coming in before the R/S so I hope (and halfway expect) to see 0.50’s in early April.
Look at the volume. It speaks .... volumes. No one (with money) cares about Pro140 or the company. There’s no assurance that FDA won’t pull some bullsh** in the coming quarters. There is no assurance from the company that mono trial is moving forward, except perhaps for the considerable dilution recently. I know now that I should have never invested here 2 years ago, because I do not have endless patience. Nonetheless, going forward I suppose CYDY is the best place to put my money.
Virtually nothing will move sp as long as we are on OTC. Even approval of combo won’t be near as much as most think.
No, I’m saying it doesn’t make sense.
I think the secrecy is so that BP can purchase the developing bios for a lower price. This has been percolating for about a year now. I try to make sense of things when they don’t make sense, but this is best (yet unsatisfactory) thing I could come up with.
I’ve no clue as to when the next cc will be. I suspect the company doesn’t know ... yet. Whenever they have a talk with the FDA I’d suspect we will hear as much as they can say. That normally isnt near as much as we’d like.
Ummm .... How is GvHD a ..... $80 Bill market ? Or did I mis-read what you said ?
Either nothing, or much less than what management wants, or hopefully bp doesn’t want to say just yet. Hopefully they won’t say until Mono results are out and GvHD finishes phase 2.
Thank you, trding. You are The One.
I understand that 10 patients have been treated and 10 have been placeboed, so I think there is 40 left to treat. Correct me if I’m wrong.
As long as we’re on OTC, I only expect 3 things to significantly move share price : partnership, buyout or FDA approval.
Lowest volume in weeks
More reasons to not expect a B O for a few quarters yet. More mono data means a higher purchase price and more paychecks.
When did the company first announce that 150 patients had enrolled in the Mono trial ?
In CYDY investor presentation of this January, they expect mono trial completion THIS YEAR. Page 17. Enrollment is not close to being completed then and the trial lasts 48 weeks. How could they possibly say the trial would be over this year ? Second half of 2019, possibly. It was at the time of release, either outdated info, or misleading info. Not a mere sliding of timelines. Sigh.
*That’s* a breakthrough ??
If 20K shares causes of 5 cent drop, then would I need to set a limit purchase order 5 cents above current price just to buy 20K shares ? I Hope to be buying more when cash becomes available.
Notice of Effectiveness ? That sounds like an FDA document more than a SEC document. All I can gather is that this is more dilution.
The ultimate support is efficacy in phase 3.
But by that time Mono data will be out, so the buyout price will be much higher.
And CYDY would be considerably slower than that.